Printer Friendly

Zosano Pharma, Inc. to Present at the 13th Annual Drug Delivery Partnerships Meeting.

Presentation to Include Update on Two New Pipeline Programs

FREMONT, Calif. -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, today announced that Dr. Peter Daddona, the company's chief scientific officer, will present at the 13th Annual Drug Delivery Partnerships Meeting in Las Vegas, NV on Thursday, January 22, 2009 at 4:45 p.m. as part of a Technology Showcase to highlight next-generation delivery technologies.

During his presentation titled "Zosano Drug-Coated Micro Projection Technology: Rapid and Effective Transdermal Delivery of PTH (1-34) for Osteoporosis," Dr. Daddona will discuss the use of Zosano's novel drug-coated microprojection technology in its lead product, the ZP-PTH rapid delivery patch for the treatment of osteoporosis, and two new pipeline programs: ZP-G-CSF (filgrastim) for the treatment of chemotherapy induced neutropenia (infection risk) and ZP-EPO for the treatment of anemia associated with chronic kidney disease.. Both preclinical-stage programs are being developed as a patch that would provide single-step therapeutic delivery and a convenient, cost effective alternative to outpatient injections.

Zosano's lead product, ZP-PTH, uses the company's unique transdermal technology, being developed as an alternative to daily injections, to deliver PTH 1-34, or teriparatide, a compound that has been proven to stimulate formation of new bone and reduce the risk of fractures. Zosano recently completed a positive phase 2 study and successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The phase 2 multi-center, double-blind, multi-dose study demonstrated that daily administration of ZP-PTH for 24 weeks was well tolerated and resulted in a significant gain in bone mineral density of the lumbar spine over placebo (p-value < 0.001). Zosano has also reached agreement with the FDA on key elements of the clinical trial and confirmation from the FDA that a 505(b)(2) regulatory filing is appropriate for the ZP-PTH patch.

About Zosano Pharma, Inc.

Zosano Pharma, Inc. is a privately held pharmaceutical company developing products for the treatment of osteoporosis, chemotherapy induced neutropenia and anemia associated with chronic kidney disease, using its novel transdermal delivery technology. Its lead clinical program, the ZP-PTH rapid delivery patch for the treatment of osteoporosis, is being developed as an alternative to currently required daily injections. Zosano's transdermal delivery technology is capable of delivering peptides, proteins, small molecules and vaccines by permeating the skin's outer layer and ensuring significant therapeutic effect. This proven proprietary technology offers several key benefits, including efficacy and safety comparable to approved injectables, needle-free delivery, a self-administered patch, rapid onset of action and room temperature storage. Zosano's transdermal delivery technology has been clinically tested in over 400 patients with four different peptides and a vaccine. Zosano aims to develop products both independently and through strategic licensing and co-development arrangements. Founded in 2006 as an ALZA Corporation spin-out led by Nomura Phase4 Ventures, Zosano is funded by New Enterprise Associates, Nomura Phase4 Ventures, HBM BioVentures and ProQuest Investments. For more information, please visit
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 19, 2009
Previous Article:MedjetAssist, The Steele Foundation Form Alliance to Create End-to-End Travel Security Suite.
Next Article:Virtual PBX Receives INTERNET TELEPHONY[R] Magazine's 11th Annual Product of the Year Award.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters